Back to all research

Thymosin Alpha-1: What the Research Says

July 7, 2026

Thymosin alpha-1 has one of the larger clinical literatures of any compound in this category, tied to its role in immune modulation. This overview summarizes what the published research reports, strictly within a laboratory-research context.

What Is Thymosin Alpha-1?

Thymosin alpha-1 (thymalfasin) is an N-terminally acetylated acidic peptide of 28 amino acids (~3,108 Da). It was the first peptide isolated from thymic tissue, originally identified for its activity in restoring immune function in thymectomized animal models.

Mechanisms Studied in Research

  • Innate-immune signaling. Research describes thymosin alpha-1 acting via Toll-like receptors on dendritic cells, initiating cytokine production.
  • T-cell modulation. Studies report effects on the proliferation, differentiation, and maturation of T cells, and on CD4+/CD8+ balance.

Clinical & Regulatory Context

Thymosin alpha-1 is marketed in more than 30 countries under the brand name ZADAXIN and has been studied in thousands of clinical-trial subjects for conditions such as chronic hepatitis B and severe infection. In the United States it has received FDA orphan-drug designations for specific indications. Importantly, that regulatory context pertains to the branded pharmaceutical — research-grade thymosin alpha-1 is not that approved product and is supplied strictly for laboratory research.

The State of the Evidence

  • Thymosin alpha-1 has a substantial clinical literature, but that evidence relates to the branded medicine and its studied indications.
  • Research-grade material is distinct from any approved product and is for laboratory research only.

Key Takeaways

  • Thymosin alpha-1 is a 28-amino-acid immune-modulating peptide, the first isolated from thymic tissue.
  • Research centers on innate-immune signaling and T-cell modulation.
  • It is marketed abroad and holds US orphan-drug designations; research-grade material is for laboratory research only.

References

  • King R., Tuthill C. “Immune Modulation with Thymosin Alpha 1 Treatment.” PMID 27450734.
  • “Thymosin alpha 1: A comprehensive review of the literature.” PMC7747025.
  • “Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.” PMC10144173.

Research Use, Legal Status & Handling

Material supplied for research is intended for in-vitro laboratory research use only. It is not a dietary supplement, drug, cosmetic, or food. Where an approved pharmaceutical version of a compound exists, research-grade material is not that approved product and is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws and regulations in their jurisdiction. Research peptides are generally stored lyophilized, protected from light and heat, with reconstitution and handling performed per standard laboratory protocols.

Disclaimer: This article is provided for educational and informational purposes only and summarizes published laboratory and, where noted, clinical research. It is not medical advice or a recommendation for any form of use. Research-grade material is intended strictly for in-vitro research use only — not for human or veterinary consumption. Always consult a qualified professional regarding health-related questions.